CorVista System
Point-of-care cardiovascular diagnostic system for early disease detection
Device · On PremiseCompany source
Company profile
About CorVista Health
CorVista Health is transforming cardiovascular diagnostics by bringing hospital-grade testing to primary care settings. The company addresses a critical gap in cardiovascular care: 69% of heart failure cases are misdiagnosed in primary care, 51% of pulmonary arterial hypertension cases in the U.S. are misdiagnosed, and 41% of heart attack patients had previously undiagnosed coronary artery disease. CorVista's technology fuses data science with disease biology to detect subtle physiologic changes, quantify autonomic patterns, systemic stress, and vascular dynamics at the point of care. The system tests for multiple cardiovascular conditions simultaneously, helping healthcare providers identify previously overlooked conditions before symptoms escalate. The company's mission is to transform cardiovascular care by moving diagnosis out of the hospital and into the doctor's office, eliminating barriers, reducing delays, and ensuring every patient receives timely, accurate diagnoses. The CorVista System with CAD Add-on and PH Add-on has received 510(k) clearance from the FDA. The technology is developed and manufactured by Analytics For Life, Inc., and licensed exclusively to CorVista Health.
Company description CorVista Health official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at CorVista Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Coronary Artery Disease
- Heart Failure
- INOCA (Ischemia with No Obstructed Coronary Arteries)
- Pulmonary Arterial Hypertension
Who it serves
- Clinics
- Healthcare Providers
- Primary Care Physicians
Deployment & integration
On Premise deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Appointed Nikki Troiano Gainey as Chief Customer Officer and Ian Shadforth as Chief Strategy Officer (May 2026). Announced collaboration with Mayo Clinic for pulmonary hypertension diagnosis (April 2026). Demonstrated high-sensitivity CAD detection including INOCA at ACC.26 conference (March 2026).
Partnerships
Recorded partners
- Analytics For Life, Inc. (manufacturer and developer)
- Mayo Clinic
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
CorVista System CAD Add-on
Add-on module for coronary artery disease detection including INOCA
Device · On PremiseCompany source
CorVista System PH Add-on
Add-on module for pulmonary hypertension diagnosis
Device · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Utility of a novel point-of-care test in detecting coronary artery disease following negative nuclear testing: a case series.European heart journal. Case reports · Feb 1, 2026
Facilitating Earlier Diagnosis of Pulmonary Hypertension Using a Novel Noninvasive Diagnostic.JACC. Case reports · Sep 3, 2025
Clinical validation of a machine-learned, point-of-care system to IDENTIFY pulmonary hypertension.ERJ open research · Sep 1, 2025
Clinical Validation of a Machine-Learned, Point-of-Care System to IDENTIFY Functionally Significant Coronary Artery Disease.Diagnostics (Basel, Switzerland) · May 8, 2024
Machine Learning Algorithms: Selection of Appropriate Validation Populations for Cardiology Research-Be Careful!JACC. Advances · Jan 1, 2023
Multicenter validation of a machine learning phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end diastolic pressure at the point-of-care.PloS one · Jan 1, 2022
Clinical validation
Clinical-trial records
Repository of Phase Signals for Pulmonary Hypertension Algorithm DevelopmentNCT04031989 · Mentioned · UNKNOWN
Regulatory
Regulatory records
CorVista® SystemK232686 · 510k · Sep 8, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
69% of heart failure cases misdiagnosed in primary care
Current standard of care gap that CorVista addresses
51% of pulmonary arterial hypertension cases misdiagnosed in U.S.
Current diagnostic challenge
41% of heart attack patients had undiagnosed CAD
Missed diagnoses with traditional testing
Mayo Clinic
Collaboration to advance next-generation pulmonary hypertension diagnosis
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Nikki Troiano Gainey
Chief Customer Officer
Ian Shadforth
Chief Strategy Officer
06 · Company updates
Updates from CorVista Health
Recent articles published on CorVista Health's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.